Jennifer A Watt1, Tara Gomes1, Susan E Bronskill1, Anjie Huang1, Peter C Austin1, Joanne M Ho1, Sharon E Straus2. 1. Division of Geriatric Medicine (Watt, Straus), University of Toronto; Li Ka Shing Knowledge Institute (Watt, Gomes, Straus), St. Michael's Hospital; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; ICES Central (Bronskill, Huang, Austin); Institute of Health Policy, Management, and Evaluation (Bronskill, Austin), University of Toronto, Toronto Ont.; ICES McMaster (Ho); Department of Medicine (Ho), McMaster University, Hamilton, Ont. 2. Division of Geriatric Medicine (Watt, Straus), University of Toronto; Li Ka Shing Knowledge Institute (Watt, Gomes, Straus), St. Michael's Hospital; Leslie Dan Faculty of Pharmacy (Gomes), University of Toronto; ICES Central (Bronskill, Huang, Austin); Institute of Health Policy, Management, and Evaluation (Bronskill, Austin), University of Toronto, Toronto Ont.; ICES McMaster (Ho); Department of Medicine (Ho), McMaster University, Hamilton, Ont. sharon.straus@utoronto.ca.
Abstract
BACKGROUND: Trazodone is increasingly prescribed for behavioural and psychological symptoms of dementia, but little is known about its risk of harm. Our objective was to describe the comparative risk of falls and fractures among older adults with dementia dispensed trazodone or atypical antipsychotics. METHODS: The study cohort included adults with dementia (excluding patients with chronic psychotic illnesses) living in long-term care and aged 66 years and older. Data were obtained from routinely collected, linked health administrative databases in Ontario, Canada. We compared new users of trazodone with new users of atypical antipsychotics (quetiapine, olanzapine or risperidone) between Dec. 1, 2009, and Dec. 31, 2015. The primary outcome was a composite of fall or major osteoporotic fracture within 90 days of first prescription. Secondary outcomes were falls, major osteoporotic fractures, hip fractures and all-cause mortality. RESULTS: We included 6588 older adults dispensed trazodone and 2875 dispensed an atypical antipsychotic, of whom 95.2% received a low dose of these medications. Compared with use of atypical antipsychotics, use of trazodone was associated with similar rates of falls or major osteoporotic fractures (weighted hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.73 to 1.07), major osteoporotic fracture (weighted HR 1.03, 95% CI 0.73 to 1.47), falls (weighted HR 0.91, 95% CI 0.75 to 1.11) and hip fractures (weighted HR 0.92, 95% CI 0.59 to 1.43). Use of trazodone was associated with a lower rate of mortality (weighted HR 0.75, 95% CI 0.66 to 0.85). INTERPRETATION: Trazodone is not a uniformly safer alternative to atypical antipsychotics, given the similar risk of falls and fractures among older adults with dementia.
BACKGROUND:Trazodone is increasingly prescribed for behavioural and psychological symptoms of dementia, but little is known about its risk of harm. Our objective was to describe the comparative risk of falls and fractures among older adults with dementia dispensed trazodone or atypical antipsychotics. METHODS: The study cohort included adults with dementia (excluding patients with chronic psychotic illnesses) living in long-term care and aged 66 years and older. Data were obtained from routinely collected, linked health administrative databases in Ontario, Canada. We compared new users of trazodone with new users of atypical antipsychotics (quetiapine, olanzapine or risperidone) between Dec. 1, 2009, and Dec. 31, 2015. The primary outcome was a composite of fall or major osteoporotic fracture within 90 days of first prescription. Secondary outcomes were falls, major osteoporotic fractures, hip fractures and all-cause mortality. RESULTS: We included 6588 older adults dispensed trazodone and 2875 dispensed an atypical antipsychotic, of whom 95.2% received a low dose of these medications. Compared with use of atypical antipsychotics, use of trazodone was associated with similar rates of falls or major osteoporotic fractures (weighted hazard ratio [HR] 0.89, 95% confidence interval [CI] 0.73 to 1.07), major osteoporotic fracture (weighted HR 1.03, 95% CI 0.73 to 1.47), falls (weighted HR 0.91, 95% CI 0.75 to 1.11) and hip fractures (weighted HR 0.92, 95% CI 0.59 to 1.43). Use of trazodone was associated with a lower rate of mortality (weighted HR 0.75, 95% CI 0.66 to 0.85). INTERPRETATION:Trazodone is not a uniformly safer alternative to atypical antipsychotics, given the similar risk of falls and fractures among older adults with dementia.
Authors: Victor I Reus; Laura J Fochtmann; A Evan Eyler; Donald M Hilty; Marcela Horvitz-Lennon; Michael D Jibson; Oscar L Lopez; Jane Mahoney; Jagoda Pasic; Zaldy S Tan; Cheryl D Wills; Richard Rhoads; Joel Yager Journal: Am J Psychiatry Date: 2016-05-01 Impact factor: 18.112
Authors: Jennifer G Naples; Mary P Kotlarczyk; Subashan Perera; Susan L Greenspan; Joseph T Hanlon Journal: Am J Geriatr Psychiatry Date: 2016-08-17 Impact factor: 4.105
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Elizabeth M Haney; Benjamin K S Chan; Susan J Diem; Kristine E Ensrud; Jane A Cauley; Elizabeth Barrett-Connor; Eric Orwoll; M Michael Bliziotes Journal: Arch Intern Med Date: 2007-06-25
Authors: Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman Journal: J Clin Psychiatry Date: 2003-02 Impact factor: 4.384
Authors: Sudeep S Gill; Susan E Bronskill; Sharon-Lise T Normand; Geoffrey M Anderson; Kathy Sykora; Kelvin Lam; Chaim M Bell; Philip E Lee; Hadas D Fischer; Nathan Herrmann; Jerry H Gurwitz; Paula A Rochon Journal: Ann Intern Med Date: 2007-06-05 Impact factor: 25.391
Authors: Noah M Ivers; Monica Taljaard; Vasily Giannakeas; Catherine Reis; Cara L Mulhall; Jonathan M C Lam; Ann N Burchell; Gerald Lebovic; Susan E Bronskill Journal: Implement Sci Commun Date: 2020-02-25
Authors: Jennifer A Watt; Zahra Goodarzi; Areti Angeliki Veroniki; Vera Nincic; Paul A Khan; Marco Ghassemi; Yonda Lai; Victoria Treister; Yuan Thompson; Raphael Schneider; Andrea C Tricco; Sharon E Straus Journal: BMJ Date: 2021-03-24
Authors: Emil Schemitsch; Jonathan D Adachi; Jacques P Brown; Jean-Eric Tarride; Natasha Burke; Thiago Oliveira; Lubomira Slatkovska Journal: Osteoporos Int Date: 2021-08-11 Impact factor: 4.507
Authors: Emad Sidhom; John T O'Brien; Adrian J Butcher; Heather L Smith; Giovanna R Mallucci; Benjamin R Underwood Journal: Int J Mol Sci Date: 2022-02-11 Impact factor: 5.923
Authors: Jennifer A Watt; Zahra Goodarzi; Areti Angeliki Veroniki; Vera Nincic; Paul A Khan; Marco Ghassemi; Yuan Thompson; Yonda Lai; Victoria Treister; Andrea C Tricco; Sharon E Straus Journal: BMC Geriatr Date: 2020-06-16 Impact factor: 3.921
Authors: Michael A Campitelli; Susan E Bronskill; Laura C Maclagan; Daniel A Harris; Cecilia A Cotton; Mina Tadrous; Andrea Gruneir; David B Hogan; Colleen J Maxwell Journal: JAMA Netw Open Date: 2021-08-02